Are "third-generation" antipsychotics (aripiprazole and others) poor augmentation choices for treatment resistant psychosis?

As aripiprazole, brexpiprazole, and cariprazine are partial-dopamine agonists with potent binding affinities to the D2 receptor, do they prevent augmentation effects (or worsen psychosis) when two...

06 November 2018 9,376 9 View